FDA Concludes That CBD Does Not Appear To Have Abuse Potential Under The CSA

On October1, 2018, the FDA publicly released its stance on cannabidiol, CBD

Dr. Brett Giroir who conducted the review noted that, "CBD also does not appear to produce physical dependence."

- "CBD does not bind to cannabinoid receptors or any other receptor associated with abuse potential."

- "CBD does not produce withdrawal signs or symptoms...This suggest that CBD does not produce physical dependence."

- "There is little evidence that CBD produces rewarding responses in animals or humans, which suggests that the drug does not produce meaningful psychological dependence."

Giroir also noted that CBD doesn’t meet the description of even the least-restrictive class of controlled substances, Schedule 5, but that international drug treaties require the nation to control the cannabis extract.